

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number  
**WO 02/061065 A2**

- (51) International Patent Classification<sup>7</sup>: **C12N 9/88**
- (21) International Application Number: **PCT/EP02/01118**
- (22) International Filing Date: 30 January 2002 (30.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
01200353.9 31 January 2001 (31.01.2001) EP
- (71) Applicant (*for all designated States except US*):  
**VLAAMS INTERUNIVERSITAIR INSTITUUT  
VOOR BIOTECHNOLOGIE VZW** [BE/BE]; Rijviss-  
chestraat 120, B-9052 Zwijnaarde (BE).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **VANCOMPER-  
NOLLE, Katia** [BE/BE]; Postlaan 9, B-9070 Heusden  
(BE).
- (74) Common Representative: **VLAAMS INTERUNIVER-  
SITAIR INSTITUUT VOOR BIOTECHNOLOGIE  
VZW**; Rijvisschestraat 120, B-9052 Zwijnaarde (BE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished  
upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: **PHOSPHORYLATED GLYOXALASE I AND ITS USE**

(57) Abstract: The present invention relates to a phosphorylated form of mammalian glyoxalase I. The present invention relates further to the use of phosphorylated mammalian glyoxalase I to modulate MG-modification of proteins (AGE formation) and consequent cell death, especially upon stress such as oxidative stress, or upon TNF treatment.

**WO 02/061065 A2**



**PHOSPHORYLATED GLYOXALASE I AND ITS USE**

The present invention relates to a phosphorylated form of mammalian glyoxalase I. The present invention relates further to the use of phosphorylated mammalian glyoxalase I to modulate methylglyoxal (MG)-modification of proteins and consequent cell death, especially upon stress such as oxidative stress, or upon TNF treatment.

Tumor Necrosis Factor (TNF) is a pleiotropic cytokine, originally described for its ability to cause hemorrhagic necrosis of certain tumors *in vivo* (Carswell et al., 1975).

In addition to its anti-tumor and anti-malignant cell effects, TNF has been reported to influence mitogenesis, differentiation and immunoregulation of various cell types.

The activities of TNF are mediated through two cell-surface receptors, namely TNF-R55 (CD120a) and TNF-R75 (CD120b), which are expressed by most cell types.

TNF's effects are mediated primarily through TNF-R55. Upon activation of the receptor, adaptor proteins such as TRADD and TRAF are recruited and bind to the intracellular part of the clustered receptor (for review, see (Wallach et al., 1999)).

These receptor-associated molecules that initiate signaling events are largely specific to the TNF/nerve growth factor receptor family. However, the downstream signaling molecules are not unique to the TNF system, but also mediate effects of other inducers. Downstream signaling molecules in the TNF system identified so far include: caspases, phospholipases, the three mitogen-activated protein (MAP) kinases, and the NF- $\kappa$ B activation cascade.

TNF-induced cell death in L929 cells is characterized by a necrosis-like phenotype and does not involve DNA fragmentation (reviewed by Fiers et al., 1999). It is independent of caspase activation and cytochrome c release, but is dependent on mitochondria and is accompanied by increased production of reactive oxygen intermediates (ROI) in the mitochondria that are essential to the death process (Goossens et al., 1995; Goossens et al., 1999). The latter was demonstrated by the fact that lipophylic anti-oxidantia when added 3h after TNF treatment could not only arrest the ongoing increased ROI production but could also arrest cell death (Goossens et al., 1995). Furthermore, the mitochondria translocate from a dispersed distribution to a perinuclear cluster (De Vos et al., 2000); functional implications of this mitochondrial translocation remain unclear.

While much effort has been directed at the molecular mechanism of the caspase-dependent cell death pathway, relatively little is known about the TNF-induced ROI-dependent cell death pathway. To identify molecules involved in the latter, we performed a comparative study of the phosphoproteins from TNF-treated and control cells by two-dimensional (2-D) gel electrophoresis. It is known that upon activation of the TNF receptor, several kinases/phosphatases are activated (Guy et al., 1992; Guy et al., 1991). However, most of the changes in phosphorylation occur very rapidly (2-15 min) upon binding of TNF to its receptors and most of them are transient and related to the gene-inductive activities of TNF.

To identify molecules that are involved in the cytotoxic process downstream of the receptor-proximal events, lysates from cells that had been stimulated with TNF for 1.5h are studied. Previously, oncoprotein 18 (Op18, stathmin) has been identified as a protein with reproducible and large increases in phosphorylation upon TNF-treatment. Op18 is responsible for TNF-induced microtubule stabilization that promotes cell death (Vancompernelle et al., 2000). Unexpectedly, we were able to demonstrate that glyoxalase I is also phosphorylated upon TNF treatment. Phosphorylation of mammalian glyoxalase I has not yet been described, although the sequence does contain several potential phosphorylation sites (Ranganathan et al., 1993). Interestingly, phosphorylation of yeast GLO1 has been observed during the sexual response of *S. cerevisiae* – specifically, during the arrest of cell division at the G1 phase, which occurs when haploid cells of one sex are exposed to the mating factor of the opposite type of cells (Inoue et al., 1990). However, none of these observations suggest that phosphorylated mammalian glyoxalase I does exist, neither which potential phosphorylation sites may be used.

Glyoxalase I, together with glyoxalase II, constitutes the glyoxalase system that is an integral component of the cellular metabolism of  $\alpha$ -ketoaldehydes and is responsible for the detoxification of the latter. The prime physiological substrate of the glyoxalase system is methylglyoxal (MG), which is cytotoxic. The major source of intracellular MG is the glycolysis namely, non-enzymatic and enzymatic elimination of phosphate from dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. The glyoxalase system, using glutathione (GSH) as cofactor, catalyzes the conversion of methylglyoxal to D-lactate in two consecutive steps. Glyoxalase I catalyses the isomerization of the hemithioacetal, produced by the nonenzymatic conjugation of

methyglyoxal with glutathione (GSH), to S-D-lactoylglutathione which is then hydrolysed by glyoxalase II to D-lactate and GSH. D-lactate is then further metabolized to pyruvate by 2-hydroxy-acid dehydrogenase localized in the mitochondria. In addition to its role as detoxification system, it has been suggested that glyoxalase I, together with its substrate MG, is involved in the regulation of cellular growth (for a review, see Kalapos, 1999), but until now this role has not been found. Increased expression of glyoxalase I occurs in diabetic patients and in some types of tumor such as colon carcinoma (Ranganathan et al., 1993), breast cancer (Rulli et al., 2001), prostate cancer (Davidson et al., 1999). It is also uniquely overexpressed in invasive human ovarian cancer compared to the low malignant potential form of this cancer (Jones et al., 2002). Also hypoxia can lead to increased expression of glyoxalase I (Principato et al., 1990). Recently, it has been shown that glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis (Sakamoto et al., 2000).

It is a first aspect of the invention to provide phosphorylated mammalian glyoxalase. The phosphorylation may be a single or a multiple phosphorylation. A preferred embodiment is a phosphorylated mammalian glyoxalase I comprising SEQ ID N° 1. Preferentially, said phosphorylated mammalian glyoxalase I is essentially consisting of SEQ ID N° 1, even more preferentially, said phosphorylated mammalian glyoxalase I is consisting of SEQ ID N° 1. Preferably, phosphorylation is carried out at position Ser 8 and/or Ser 21 and/or Ser 26 and/or Thr 107. Even more preferably, the phosphorylation is carried out at the PKA phosphorylation sites Ser 45 and/or Thr 98 (numbering as for human glyoxalase, including the N-terminal Met residue)

Another aspect of the invention is the use of a phosphorylated glyoxalase I to modulate MG-modification of proteins. Said phosphorylated glyoxalase I may be any glyoxalase I, known to the person skilled in the art, such as a fungal glyoxalase I or a plant glyoxalase I. Preferably, said glyoxalase I is a mammalian glyoxalase I. MG-modified proteins or advanced glycation end products (AGEs) are known to be synthesized in response upon a number of pathophysiological conditions *in vivo*, such as cataract formation (Shamsi 2000), vascular complications associated with chronic diabetes (Shinohara et al., 1998), tissue damage after ischemia/reperfusion (Oya et al., 1999) and aging (Corman et al., 1998). The term AGE, as used here, is used for any MG-modification of a protein, irrespective the way it is formed; the term MG-

modification of proteins is considered as being equivalent with the term AGE formation.

Still another aspect of the invention is the use of phosphorylated glyoxalase I, or an inhibitor of the phosphorylation of glyoxalase I, preferably mammalian glyoxalase I to modulated TNF induced cell death. Said inhibitor can be any inhibitor that inhibit the phosphorylation of glyoxalase I; preferably said inhibitor is an inhibitor of the PKA activity.

Alternatively, a mutant form of glyoxalase I may be used that is affected in its phosphorylation ("phosphorylation mutant"), i.e. it cannot longer be phosphorylated at one or more phosphorylation sites, and/or it becomes phosphorylated at other sites. On the base of the knowledge of the phosphorylation sites, such mutants can be easily constructed by the person skilled in the art and include, as a non-limiting example, glyoxalase I forms where the Ser 45 and/or the Thr 98 have been replaced by another amino acid or any other mutant that affects phosphorylation on these or other sites. Therefore, another aspect of the invention is the use of a phosphorylation mutant of glyoxalase I, preferably mammalian glyoxalase I, to modulate TNF-induced cell death. This modulation can be realized by replacing the endogenous glyoxalase I by the mutant form, or by expressing the mutant glyoxalase I form beside the endogenous glyoxalase I.

A further aspect of the invention is the use of phosphorylated glyoxalase I, or an inhibitor of the phosphorylation of glyoxalase I, or a phosphorylation mutant of glyoxalase I, to modulate stress induced cell death. Preferably, said stress is oxidative stress. Oxidative stress, followed by ROI induction and AGE formation is known to occur in several organisms, including plants, yeast, fungi and mammals. A preferred embodiment is the use of mammalian phosphorylated glyoxalase I to modulate oxidative stress induced cell death.

Still another aspect of the invention is the use of PKA to phosphorylate glyoxalase I. By modulating the phosphorylation of glyoxalase I, TNF induced cell death and stress induced cell death, preferably oxidative stress, can be modulated.

## BRIEF DESCRIPTION OF THE FIGURES

**Figure 1:** phosphorylation of glyoxalase I in control cells (left panel) and after 1.5 h of TNF treatment (right panel).

**Figure 2:** effect of the glyoxalase I inhibitor S-p-bromobenzylglutathione diester on TNF-induced cytotoxicity in L929s cells, in function of the incubation time. TNF is added at a concentration of 1000 units/ml; the inhibitor is added 1h10min prior to TNF at a concentration of 10  $\mu$ M (GI10) or 20  $\mu$ M (GI20). The time scale is calculated from the moment of TNF addition.

**Figure 3:** western blots, developed with anti-human glyoxalase I polyclonal antibody, of 2-dimensional gels (pH 3-10) from total cell lysates derived from control cells (C), glyoxalase I inhibitor S-p-bromobenzylglutathione diester treated cells (I), TNF treated cells (TNF) and cells treated with TNF and glyoxalase I inhibitor (TNF + I).

**Figure 4:** effect of different concentrations exogenously added methylglyoxal on TNF-induced cell death. Measurement after 5,5 h of incubation with TNF and methylglyoxal at a concentration as indicated.

**Figure 5:** effect of different concentrations of the AGE formation inhibitor, aminoguanidine, on the TNF-induced cell death. Measurement after 16h of incubation with TNF and aminoguanidine at a concentration as indicated.

**Figure 6:** inhibition of TNF induced cell death by the PKA inhibitor H89, in function of the incubation time. The concentration of the inhibitor H89 is as indicated on the graph.

**Figure 7:** western blot of a 2-dimensional gel (IEF pH 4 - 7) developed with a polyclonal antibody against human GLO1. C: control, TNF: TNF treated sample, H89: control sample with addition of the PKA inhibitor H89, TNF + H89: TNF treated sample, with addition of the PKA inhibitor H89. Ac and Bs indicate the acidic (Ac) and basic (Bs) side of the gel. Upon TNF-treatment of the cells, a more acidic isoform of GLO1 becomes apparent; the arrow indicates the more acidic phosphorylated form. This new isoform is derived from the most basic isoform, present in the control cells, and its formation is inhibited by the presence of the PKA inhibitor H89. Note that the two dimensional pattern of the TNF-treated sample in the presence of H89 is identical to the control sample C and the control sample H89.

**Figure 8:** Formation of a specific MG-derived AGE during TNF-induced cell death and the inhibition by several agents.

**A.** Western blot with the anti-AGE antibody mAb6B that was developed against MG-modified keyhole limpet hemocyanin (recognizes also MG-modified BSA). Immunocomplexes were visualized by enhanced chemiluminescence (ECL) and evaluated by scanning densitometry. To analyse AGE formation in TNF-induced cell

death, all TNF treatments (1000 U/ml, 2.5-h) were done in the presence of cycloheximide (CHX) to synchronize cell death.

Equal amounts of total cytosolic protein from cells incubated under different conditions were loaded in each lane. a: control cells; b: TNF-treated cells; c: control anti-oxidant butylated hydroxyanisole (BHA; 100  $\mu$ M); d: TNF-treated cells in the presence of BHA (100  $\mu$ M), the anti-oxidant agent BHA was administered 0.5h after TNF administration to allow initiation of TNF signalling; e: control 2-deoxyglucose; f: TNF-treated cells in the presence of 2-deoxyglucose (2:1 ratio to glucose), 2-deoxyglucose was administered at the same time as TNF. Note the appearance of the specific MG-derived AGE exclusively in TNF-treated cells (indicated by arrowheads), while no significant changes in the other AGEs can be observed. The formation of this MG-derived AGE is strongly inhibited (65%) in the presence of BHA or 2-deoxyglucose.

B. Formation of the specific MG-derived AGE is inhibited by the inhibitors that also inhibit the phosphorylation of GLO1. This figure represents the percentage relative increase of the ECL signal (as evaluated by scanning densitometry) of this specific MG-derived AGE in TNF-treated cells (1000 U/ml in the presence of CHX, 1.5-h) over the background in control cells.

**Figure 9:** The anti-glucose metabolite 2-deoxyglucose strongly inhibits TNF-induced cell death in L929 cells.

TNF-induced cell death was measured as a function of time by flow cytometry using propidium iodide (PI) uptake as parameter for the percentage of death cells. 2-Deoxyglucose was used in a 2:1 ratio to glucose.

## EXAMPLES

### *Materials and methods to the examples*

#### Cell lines and cultures

All L929 cells were cultured in Dulbecco's modified Eagle's medium supplemented with heat-inactivated fetal calf serum (5% v/v), heat-inactivated newborn calf serum (5% v/v), penicillin (100 units/ml), streptomycin (0.1 mg/ml), and L-glutamine (2mM), at 37°C in a humidified incubator under a 5% CO<sub>2</sub> atmosphere.



## Reagents

Murine TNF (mTNF) was obtained from Roche Diagnostics, and was used at 1000 IU/ml unless indicated otherwise. Propidium iodide (PI) and cycloheximide (CHX) (all from Sigma) were used at concentrations of 30  $\mu$ M and 50  $\mu$ g/ml, respectively.

### 5 Measurement of TNF-induced cell death by flow cytometry

Cell death in L929 was induced by addition of TNF to the cell suspension. Cell death was measured by quantifying PI-positive cells by FACS (FACSCalibur, Becton Dickinson, San Jose, CA). The PI dye was excited with an argon-ion laser at 488 nm; PI fluorescence was measured above 590 nm using a long-pass filter. Routinely,  
10 3,000 cells were analyzed. Cell death is expressed as the percentage of PI-positive cells in the total cell population.

### Radiolabeling of cells and preparation of the sub-cellular protein fractions

L929 cells were plated 48 h prior to the experiment.  $^{32}$ P labeling was carried out as  
15 described in (Guy et al., 1992). TNF treatments (1000 IU/ml, 1.5 h) were done in the presence of cycloheximide (CHX), to synchronize cell death. To simplify the 2-D phosphoprotein pattern and subsequent computer-assisted analysis, we prepared two subcellular protein fractions. The cytosolic protein fraction, containing soluble cytoplasmic molecules and molecules derived from single-membrane organelles, was  
20 obtained as the supernatant from digitonin (0.03%)-permeabilised cells. After rinsing once with excess PBS buffer, the remaining cell fraction was lysed in a CHAPS (2%)-containing buffer as described in (Guy et al., 1992). This lysate was then centrifuged (20,000g) and the supernatant was used as the organelle fraction; it is enriched for mitochondrial and cytoskeleton-derived proteins.

### 25 Two-dimensional (2D) gel electrophoresis

*Isoelectric focusing.* Isoelectric focusing was carried out on 18 cm IPG strips, pH 4-7 (Amersham Pharmacia Biotech), according to the manufacturer's instructions. Protein samples were precipitated with ethanol and redissolved in lysis buffer.

*SDS-PAGE.* The second dimension (SDS-PAGE) was run on large vertical gels (12.5  
30 % acrylamide, Biorad).

### Western blotting

Proteins were separated by SDS-PAGE (12.5 %) and transferred to a PVDF membrane (Hybond-P, Amersham Pharmacia Biotech). The blots were incubated with  
5 an anti-human glyoxalase I antibody (kindly provided by Dr. P. Thornalley, university of Essex, UK), followed by ECL-based detection (reagents of Amersham Pharmacia Biotech; software for analysis by Totallab).

### Amino acid sequence analysis by MALDI-mass spectrometry

Following in-gel digestion of the excised protein with endoproteinase Lys-C  
10 (sequencing grade; Boehringer, Mannheim, Germany)., a 10% aliquot of the generated peptide mixture was purified and concentrated on Poros® 50 R2 beads (Gevaert et al., 1998; Gevaert et al., 1997) and used for MALDI-MS peptide mass fingerprint analysis. However, partly due to contamination with human keratin  
15 peptides, the obtained peptide mass map did not lead to any unambiguous protein identification in a non-redundant protein database. Therefore the remainder of the peptide mixture was separated by RP-HPLC, a total of 20 fractions containing eluting peptides were obtained, which were all analysed by MALDI-MS. Adequate peptide  
20 ions were further selected for post-source decay (PSD) analysis (Spengler et al., 1992). A PSD-spectrum obtained from a peptide ion with a mass of 902.42 Da (measured in linear mode) present in the first RP-HPLC fraction, could be unambiguously assigned to the peptide NH<sub>2</sub>-SLDFYTR-COOH present in human glyoxalase I (database entry number 417246) using the SEQUEST algorithm and a non-redundant protein database. Following a search in an EST-database the same peptide sequence was identified in many different mouse EST-clones. The identified  
25 peptide contains an arginine residue at its C-terminus instead of a lysine; an observation which we made several times when endoproteinase Lys-C was used as the protease.

In order to confirm our initial finding, PSD-analysis was conducted on a peptide with an apparent mass of 1396.53 Da present in RP-HPLC fraction 11. Based on the  
30 partially <sup>18</sup>O-labelled y-type fragment ions, a peptide sequence tag (391.24)YAI/LF(885.67) could easily be obtained. Furthermore a SEQUEST-search in a non-redundant protein database lead to the identification of the peptide NH<sub>2</sub>-

FSLYFLAYEDK-COOH also belonging to human glyoxalase I. Again the same peptide sequence was found in different mouse EST-clones using the PSD-data and a SEQUEST-search in an EST-database. Based upon the amino acid sequence of human glyoxalase I, masses of peptide ions observed in the different RP-HPLC fractions could be assigned to the identified protein. Hereby, a total of 38% of the amino acid sequence of the protein was covered, again confirming the identification of glyoxalase I.

#### Assay of glyoxalase I activity

The glyoxalase I assay was performed according to a spectrophotometric method monitoring the increase in absorbance at 240 nm due to the formation of S-D-lactoylglutathione for 4 min at 20°C. The standard assay mixture contained 2 mM MG and 2 mM GSH in a sodium phosphate buffer (50 mM, pH 6.6). Before initiating the reaction by adding the total cytosolic protein fraction to the assay mixture, the mixture was allowed to stand for 10 min to ensure the equilibration of hemithioacetal formation.

#### D-Lactate measurements

D-Lactate measurements were performed by a fluorimetric assay using an endpoint enzymatic assay with D-lactate dehydrogenase (McLellan et al. 1992).

#### Intracellular methylglyoxal measurements

Intracellular free methylglyoxal is detected as the 2-methylquinoxaline (2-MQ) derivative of methylglyoxal formed with o-phenylenediamine (o-PD) using the general approach of (Chaplen et al., 1996). Samples arrived frozen on dry ice and were stored at 20 °C until assayed. Samples were thawed at room temperature and maintained on ice during the assay procedure. Sample volume was increased to 2.5 ml with MilliQ water and the samples were sonicated (5 s, 30 W). 5 M HClO<sub>4</sub> (PCA; 0.25 ml) was added to precipitate macromolecules and the resulting mixture was incubated on ice for 20 min. Samples were then centrifuged (12,000xg, 10 min) to remove precipitated materials. The supernatant was passed through a C-18 SPE cartridge (Waters Sep-

Pak tC18 plus cartridge, Millipore Corp, Marlborough, MA) that had been prepared by flushing with 6-8 ml of acetonitrile followed by 6-8 ml of 10 mM KH<sub>2</sub>PO<sub>4</sub> (pH 2.5, adjusted with concentrated H<sub>3</sub>PO<sub>4</sub>). The pre-derivatization SPE step removes phenol red and other interfering compounds. Samples were supplemented with 12.5 nmol 5-methylquinoxaline (5-MQ; internal standard) and 250 nmol o-PD (derivatizing agent) and reacted at 20 °C for 3.5 to 4 h.

#### *Sample Concentration*

All samples are concentrated after derivatization. For concentration, the samples are passed through a C-18 SPE cartridge, prepared as described above, at a rate of 1-2 ml/min. The cartridges are then rinsed with 1-2 ml 10 mM KH<sub>2</sub>PO<sub>4</sub> (pH 2.5) and the retentate eluted with 2 ml of acetonitrile. Eluates were evaporated to a volume of 200 ml using a Savant Speed-Vac Concentrator vacuum centrifugation unit (Savant Instruments, Farmingdale, NY) and filtered through 0.2-mm Gelman PVDF filters (Fisher Scientific, Chicago, IL) into sample vials.

#### *HPLC of Quinoxalines*

HPLC was performed as described previously (Chaplen et al., 1996) but with a mobile phase consisting of 35% acetonitrile/0.1% trifluoroacetic acid, pH 2.4 and 65% 10 mM phosphate/0.1% trifluoroacetic acid in HPLC grade water, pH 2.4. Under these modified conditions, 2-MQ eluted after 7.5 min and 5-MQ eluted after 11.2 min.

#### Detection of MG-derived AGEs

L929 cells were seeded 48-h prior to the experiment. TNF incubations (1000 U/ml) were done in the presence of CHX to synchronize cell death. After TNF incubations (1.5h or 2.5h), the cells were rinsed 3 times with ice-cold PBS buffer and cell lysates were prepared in a CHAPS-containing cytosol extraction buffer (Guy et al., 1992). MG-derived AGEs were detected by Western blotting using the mAb6B (Oya et al., 1999). To use the antibody sparingly, SDS-PAGE gels were only run over a distance of 5cm.

#### ***Example 1: TNF induces increased phosphorylation of Glyoxalase I***

Fig. 1 shows the autoradiogram of the two-dimensional gels from TNF-treated and control samples that were derived from cells labeled with <sup>32</sup>P-orthophosphate. The protein spot with increased phosphorylation identified as glyoxalase I is indicated by

an arrow. It was identified by mass spectrometry analysis of a peptide mixture derived from an in-gel digestion of the excised protein spot. The increased phosphorylation of glyoxalase I is already observed after 15 min of TNF treatment, but is much more pronounced after 1.5h of TNF treatment (Fig. 1). This indicates that the TNF-induced phosphorylation of GLO1 is an early but lasting event.

***Example 2: The Glyoxalase I inhibitor S-p-bromobenzylglutathione cyclopentyl diester inhibits TNF-induced cell death***

To examine the role of glyoxalase I in TNF-induced cell death, we tested the effect of the cell permeable competitive inhibitor of glyoxalase I S-p-bromobenzylglutathione diester on cell death. Preincubation (1h10min) of L929 cells with this inhibitor strongly inhibits TNF-induced cell death in a concentration dependent manner (Fig. 2). An inhibition of 60% was obtained at a concentration of 20  $\mu$ M of the inhibitor. However, when the inhibitor and TNF were added at the same time, a synergistic effect on TNF-induced cell death was obtained (50% increase in cell death at a concentration of 20  $\mu$ M of the inhibitor). This synergistic effect is more pronounced at lower doses of TNF; that is, when the cells die more slowly.

***Example 3: The Glyoxalase I inhibitor S-p-bromobenzylglutathione cyclopentyl diester inhibits the TNF-induced phosphorylation of glyoxalase I***

This differential effect of the inhibitor on TNF-induced cell death prompted us to investigate whether the binding of the inhibitor to GLO1 competes and thus inhibits the TNF-induced phosphorylation of GLO1. Fig.3 shows the Western blots, developed with an anti-human glyoxalase I polyclonal antibody, of 2-dimensional gels (pH 3-10) from total cell lysates derived from TNF-treated and control cells and from TNF-treated and control cells that were first preincubated with the glyoxalase I inhibitor for 1h10min. In the upper panels, you can see that TNF induces a more acidic phosphoisoform of glyoxalase I which is not well separated from the non-phosphorylated form (fills the space between the most left isoform and the main non-phosphorylated form). In the lower panels, you can see that in the presence of the glyoxalase I inhibitor TNF cannot induce the more acidic phosphoisoform of glyoxalase I (identical 2-D patterns as in the control). These data show that the competitive inhibitor of glyoxalase I S-p-bromobenzylglutathione inhibits the TNF-induced phosphorylation of GLO1 and that phosphorylated glyoxalase I is essential

for cell death. These data also suggest that phosphorylation of glyoxalase I modulates the active site of the enzyme.

Thus, the differential effect of the GLO1 inhibitor on TNF-induced cell death can be explained as follows:

- when the cells are pre-treated with the inhibitor, the inhibitor is already bound to GLO1 and thus hinders the TNF-induced phosphorylation of GLO1 which then leads to inhibition of phosphorylated GLO1-mediated MG-modification of proteins and consequent cell death.
- however, when the cells are treated with the inhibitor and TNF together, the TNF-induced phosphorylation of GLO1 occurs first (via a receptor-activated kinase cascade) and the inhibitor can only bind to non-phosphorylated GLO1 (and not to phosphorylated GLO1) leading to inhibition of GLO1 and thus to accumulation of MG, resulting in phosphorylated GLO1-mediated MG-modification of proteins and consequent cell death.

***Example 4: TNF-induced phosphorylation of glyoxalase I does not inhibit methylglyoxal detoxification***

For many years,  $\alpha$ -ketoaldehydes, exemplified by methylglyoxal, have been known to be carcinostatic, but their direct use as anti-cancer drugs is prevented by their rapid detoxification *in vivo* by the glyoxalase system. Therefore, glyoxalase I inhibitors have been developed as potential anti-cancer agents (Vince and Wadd, 1969; Thornalley et al., 1996). Bearing this in mind, one would expect that TNF-induced phosphorylation of GLO1 would result in inhibition of the enzyme and thus in accumulation of MG with cytotoxicity as a consequence. However, our experiments with the GLO1 inhibitor do not support this expectation, because we would then expect a synergistic effect of the pre-incubated inhibitor on TNF-induced cell death. Indeed, measurements of GLO1 activity in lysates derived from TNF-treated and control cells showed no inhibition, but even a limited increase in GLO1 activity in TNF-treated cells. These experiments were repeated several times and each time gave the same results, with an average increase of 8% after 1h of TNF-treatment and 12% (from  $0,086 \pm 0,003$  to  $0,106 \pm 0,001$  units per  $8,5\mu\text{g}$  of total protein) after 1.5h of TNF-treatment. Measurement of the concentration of the end product of the glyoxalase system D-lactate showed an increase of 60% after 1.5h of TNF-treatment compared

to control cells. This further confirmed that TNF did not inhibit GLO1 activity and that an increased flux of MG is converted through the glyoxalase system in TNF-treated cells.

5     ***Example 5: TNF increases the intracellular concentrations of methylglyoxal***

As we consider it very unlikely that TNF would cause an increased detoxification of MG through the glyoxalase system, a more plausible explanation is that TNF induces an increase in the intracellular concentrations of MG via a pathway other than inhibition of glyoxalase I. An increase in the intracellular concentration of MG would then also automatically result in an increased flux of MG through the glyoxalase system and an increased GLO1 activity. Therefore, intracellular concentrations of MG were measured with a method that not only measures free MG, but also MG bound to biological molecules (majority of the MG), mainly proteins (Chaplen et al., 1998). Two independent experiments were performed in which intracellular concentrations of MG were measured in TNF-treated (1,5h) L929 cells compared to control cells. Each sample was measured in triplicate and each time gave very reproducible results. These results showed that TNF strongly increased the intracellular concentrations of MG, with an increase of 32% (from 0,91µMole in control cells to 1,20µMole in TNF-treated cells) in the one experiment and 94% (from 1,24µMole in control cells to 2,39µMole in TNF-treated cells) in the other experiment.

Also, exogeneously added MG is strongly synergistic with TNF-induced cell death in a concentration dependent manner (Fig 4), while MG alone and used at the same concentrations is not cytotoxic for L929 cells. The synergistic effect of exogeneously added MG is more pronounced at lower doses of TNF (100 U/ml) and also earlier in TNF treatment. This result can be explained by the fact that the TNF-induced increase of endogeneous MG is more drastic at higher doses of TNF (1000U/ml) and later in TNF treatment.

30     ***Example 6: Inhibition of AGE formation inhibits TNF-induced cell death***

Increased endogenously produced levels of dicarbonyls, especially methylglyoxal, are involved in numerous pathogenic processes *in vivo*, including the formation of advanced glycation end-products (AGEs) which contribute to the pathophysiology of aging and to complications associated with chronic diabetes. They have been

detected in several pathophysiological conditions *in vivo*, such as cataract formation, vascular complications in diabetes, and tissue damage after ischemia/reperfusion. All these conditions are characterized by increased oxidative stress, and recently it was shown that mitochondrial ROS are the direct cause of increased concentrations of MG and thus AGEs formation in diabetic hyperglycaemia (Nishikawa et al., 2000). Since TNF-induced cell death in L929 cells is characterized by increased production of mitochondrial ROS (Goossens et al., 1995; Goossens et al., 1999) which are essential for cell death and increased levels of MG, we tested whether irreversible protein modification by MG plays a role in TNF-induced cell death. For this we used aminoguanidine, a nucleophilic hydrazine compound and inhibitor of advanced nonenzymatic glycosylation product formation (Brownlee et al., 1986). The percentage of cell death in L929 cells after 16h of TNF treatment (20 U/ml) with and without aminoguanidine is shown in Fig. 5. A maximum inhibition of cell death of 25% was obtained in the presence of 600 or 800  $\mu$ M of aminoguanidine and 15% inhibition in the presence of 400 $\mu$ M. This inhibition was less pronounced (average of 15% to 20%) when the cells died more rapidly by giving higher doses of TNF (500-1000U/ml). This could be due to the fact that the reaction of aminoguanidine with MG and MG-modified proteins is rather slow and that the MG protein modifications that occur during TNF-induced cell death are more rapid at higher doses of TNF and could even be enzymatically catalysed. These data indicate that irreversible protein modification by methylglyoxal might play a role in TNF-induced cell death.

***Example 7: The PKA inhibitor inhibits TNF-induced cell death and TNF-induced phosphorylation of glyoxalase I***

As it has been already shown that PKA is activated by TNF (Zhang et al., 1988), we examined whether pretreatment (2h) of L929 cells with the PKA inhibitor H89 had an effect on TNF-induced cell death. As shown in Fig. 6, the PKA inhibitor inhibits TNF-induced cell death in a concentration-dependent fashion and to a similar extent as the glyoxalase I inhibitor. Even an inhibitory effect was already obtained at relatively low concentrations of the inhibitor (1  $\mu$ M), while at the highest concentration (5  $\mu$ M) an inhibition of more than 50% was obtained. These data thus indicate that PKA plays a role in TNF-induced cell death. Next, we examined whether PKA was also responsible for the TNF-induced phosphorylation of endogenous glyoxalase I in L929 cells. As shown in Fig. 3 and Fig. 7, pretreatment of the cells with the PKA



inhibitor (5 $\mu$ M) completely abolished the induction of the more acidic isoform by TNF. This suggests that the inhibitory effect of the PKA inhibitor on TNF-induced cell death could be largely due to the inhibition of phosphorylation of glyoxalase I.

5     **Example 8: Formation of a specific methylglyoxal-derived AGE during TNF-induced cell death**

Given the demonstrated role of MG in AGE formation and the accumulation of MG noted in response to TNF treatment, we next sought to determine whether irreversible protein modification by MG is a critical step in TNF-induced cell death. Immunoblots  
10    of L929 protein extracts were performed with a monoclonal antibody raised against *in vitro* MG-modified keyhole limpet hemocyanin. This antibody (mAb6B) recognizes epitopes in arterial walls of diabetic kidneys and of tissue injured by ischemia/reperfusion (Oya et al., 1999). The immunoblots showed a distinct differential protein band specifically present in TNF-treated (2.5-h) cells along with  
15    several protein bands that were present in both the control and TNF-treated cells (Fig. 2A). The band was already present, although very weakly, after 1.5-h of TNF treatment. These data indicate that protein modification by MG is not a random process during TNF-induced cell death, but rather involves specific target molecules for MG.

20       To demonstrate that the TNF-induced MG-derived AGE identified here by the antibody was formed as a consequence of oxidative stress, as in the case of diabetic hyperglycemia (Nishikawa et al., 2000), and only under cytotoxic conditions, L929 cells were treated with the anti-oxidant BHA. BHA arrests TNF-induced ROS production and cell death (Goossens et al., 1995). The formation of this specific MG-  
25    derived AGE in TNF-treated cells, as measured by densitometric analysis of the ECL signal from immunoblots, was reduced by 65% in the presence of BHA (Fig. 8A). The anti-glucose metabolite 2-deoxyglucose was then used to determine whether the TNF-induced increase in MG concentration was derived from glycolytic intermediates, which are usually considered to be the main intracellular source of MG. In the  
30    presence of 2-deoxyglucose (2:1 ratio to glucose), TNF-induced cell death was inhibited by 65% (Fig. 9), as was the formation of the specific MG-derived AGE noted in Fig. 8A. The possibility exists that inhibition of AGE formation in the presence of 2-deoxyglucose is an indirect result of the inhibition of mitochondrial ROS, which would mean the latter are derived from increased glycolysis. Indeed, it has been reported

that TNF highly increases glycolysis and glucose uptake in L929 cells (Matthews, 1983; Kim and Kim, 2001).

Taken together, our results clearly indicate that glycolysis plays an important role in TNF-induced necrosis and that TNF-induced mitochondrial ROS, as in diabetic hyperglycemia, can lead to accumulation of MG and subsequent formation of a specific MG-derived AGE.

***Example 9: The TNF-induced phosphorylation of GLO1 is involved in formation of the specific MG-derived AGE***

Until now, AGE formation has been described as non-enzymatic, irreversible modifications of Lys and Arg residues slowly formed through long-term exposure to high concentrations of sugars and reactive compounds such as MG. Yet in TNF-induced cell death, MG-modification of proteins occurs very rapidly (within 1.5- to 2.5-h of initiating TNF treatment). This suggests that MG-modification of specific target molecules could be enzymatically catalyzed by phosphorylated GLO1. To test this hypothesis, L929 cells were pretreated with s-p-bromobenzylglutathione cyclopentyl diester (BBGD 20  $\mu$ M; kindly provided by Dr. P Thornalley) and the PKA inhibitor H89 (5  $\mu$ M), respectively, to determine whether these inhibitors of GLO1 phosphorylation interfere with the formation of MG-derived protein modifications during TNF-induced cell death. In cell cultures pre-treated with BBGD and the PKA inhibitor, the formation of the specific MG-derived AGE, which is recognized by mAb6B, as measured by densitometric analysis of the ECL signal from immunoblots, was reduced by 50% and 70%, respectively, after 1.5-h of TNF treatment (Fig 8B). Inhibition was less pronounced (10% and 20% respectively) after 2.5-h of TNF treatment, which could be due to the fact that, at later time points of TNF treatment, MG accumulation is dominant over the low basal levels of the phosphorylated form of GLO1 which are always present in L929 cells. The inhibitory effects with pre-treatment of BBGD on TNF-mediated AGE formation and cell death is less pronounced during longer TNF treatments, possibly as a consequence of MG accumulation as described above. In any event, these data indicate that formation of the specific MG-derived AGE during cell death requires the TNF-induced phosphorylation of GLO1.

**REFERENCES**

- Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P., and Cerami, A. (1986). Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. *Science* 232, 1629-1632.
- 5 Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Fiore, N., and Williamson, B. (1975). An endotoxin-induced serum factor that causes necrosis of tumors. *Proc. Natl. Acad. Sci. U. S. A* 72, 3666-3670.
- Chaplen, F.W., Fahl, W.E., and Cameron, D.C. (1998). Evidence of high levels of methylglyoxal in cultured Chinese hamster ovary cells. *Proc. Natl. Acad. Sci. U. S. A* 95, 5533-5538.
- 10 Chaplen, F.W.R., Fahl, W.E., and Cameron, D.C. (1996). Method for determination of free intracellular and extracellular methylglyoxal in animal cells grown in culture. *Anal. Biochem.* 238, 171-178.
- Corman, B., Duriez, M., Poitevin, P., Heudes, D., Bruneval, P., Tedgui, A., and Levy, B.I. (1998). Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. *Proc. Natl. Acad. Sci. U. S. A* 95, 1301-1306.
- 15 Davidson, S.D., Cherry, J.P., Choudhury, M.S., Tazaki, H., Mallouh, C., and Konno, S. (1999). Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy. *J. Urol.* 161, 690-691.
- 20 De Vos, K., Severin, F., Van Herreweghe, F., Vancompernelle, K., Goossens, V., Hyman, A., and Grooten, J. (2000). Tumor necrosis factor induces hyperphosphorylation of kinesin light chain and inhibits kinesin-mediated transport of mitochondria. *J. Cell Biol.* 149, 1207-1214.
- Fiers, W., Beyaert, R., Declercq, W., and Vandenabeele, P. (1999). More than one way to die: apoptosis, necrosis and reactive oxygen damage. *Oncogene* 18, 7719-7730.
- 25 Gevaert, K., Demol, H., Puype, M., Broekaert, D., De Boeck, S., Houthaeve, T., and Vandekerckhove, J. (1997). Peptides adsorbed on reverse-phase chromatographic beads as targets for femtomole sequencing by post-source decay matrix assisted

laser desorption ionization-reflectron time of flight mass spectrometry (MALDI-RETOF-MS). *Electrophoresis* 18, 2950-2960.

Gevaert, K., Demol, H., Sklyarova, T., Vandekerckhove, J., and Houthaeve, T. (1998). A peptide concentration and purification method for protein characterization in the subpicomole range using matrix assisted laser desorption/ionization-postsource decay (MALDI-PSD) sequencing. *Electrophoresis* 19, 909-917.

Goossens, V., De Vos, K., Vercammen, D., Steemans, M., Vancompernelle, K., Fiers, W., Vandenabeele, P., and Grooten, J. (1999). Redox regulation of TNF signaling. *Biofactors* 10, 145-156.

Goossens, V., Grooten, J., De Vos, K., and Fiers, W. (1995). Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. *Proc. Natl. Acad. Sci. U. S. A* 92, 8115-8119.

Guy, G.R., Cao, X., Chua, S.P., and Tan, Y.H. (1992). Okadaic acid mimics multiple changes in early protein phosphorylation and gene expression induced by tumor necrosis factor or interleukin-1. *J. Biol. Chem.* 267, 1846-1852.

Guy, G.R., Chua, S.P., Wong, N.S., Ng, S.B., and Tan, Y.H. (1991). Interleukin 1 and tumor necrosis factor activate common multiple protein kinases in human fibroblasts. *J. Biol. Chem.* 266, 14343-14352.

Inoue, Y., Choi, B.Y., Murata, K., and Kimura, A. (1990). Sexual response of *Saccharomyces cerevisiae*: phosphorylation of yeast glyoxalase I by a cell extract of mating factor-treated cells. *J. Biochem. (Tokyo)* 108, 4-6.

Jones, M.B., Krutzsch, H., Shu, H., Zhao, Y., Liotta, L.A., Kohn, E.C., and Petricoin, E.F., III (2002). Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. *Proteomics*. 2, 76-84.

Kalapos, M.P. (1999). On the promine/retine theory of cell division : now and then. *Biochem. Biophys. Acta* 1426, 1-16.

Kim, Y. H. and Kim, S. S. Bcl-2 in L929 cells inhibits tumor necrosis factor-mediated increase in glycolysis and accelerates tricarboxylic acid cycle. *Cancer Detection and Prevention*, 24 (Supplement 1). 2001.

Matthews, N. (1983). Anti-tumour cytotoxin produced by human monocytes: studies on its mode of action. *Br. J. Cancer* 48, 405-410.

McLellan, A.C., Phillips, S.A., Thornalley, P.J. (1992). Fluorometric assay of D-lactate. *Anal. Biochem.* 206 (1), 12-16.

- 5 Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M.A., Beebe, D., Oates, P.J., Hammes, H.P., Giardino, I., and Brownlee, M. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature* 404, 787-790.

- 10 Oya, T., Hattori, N., Mizuno, Y., Miyata, S., Maeda, S., Osawa, T., and Uchida, K. (1999). Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. *J. Biol. Chem.* 274, 18492-18502.

Principato, G.B., Talesa, V., Norton, S.J., Contenti, S., Mangiabene, C., and Rosi, G. (1990). Induction of mouse liver glyoxalase I by hypobaric hypoxia. *Biochem. Int.* 20, 1019-1023.

- 15 Ranganathan, S., Walsh, E.S., Godwin, A.K., and Tew, K.D. (1993). Cloning and characterization of human colon glyoxalase-I. *J. Biol. Chem.* 268, 5661-5667.

Rulli, A., Carli, L., Romani, R., Baroni, T., Giovannini, E., Rosi, G., and Talesa, V. (2001). Expression of glyoxalase I and II in normal and breast cancer tissues. *Breast Cancer Res. Treat.* 66, 67-72.

- 20 Sakamoto, H., Mashima, T., Kizaki, A., Dan, S., Hashimoto, Y., Naito, M., and Tsuruo, T. (2000). Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. *Blood* 95, 3214-3218.

- 25 Shamsi, F.A., Sharkey, E., Creighton, D. and Nagaraj, R.H. (2000). Maillard reactions in lens proteins: methylglyoxal-mediated modifications in the rat lens. *Exp Eye Res* 70, 369-380.

Shinohara, M., Thornalley, P.J., Giardino, I., Beisswenger, P., Thorpe, S.R., Onorato, J., and Brownlee, M. (1998). Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents

hyperglycemia-induced increases in macromolecular endocytosis. *J. Clin. Invest* **101**, 1142-1147.

Spengler, B., Kirsch, D., Kaufmann, R., and Jaeger, E. (1992). Peptide sequencing by matrix-assisted laser-desorption mass spectrometry. *Rapid Commun. Mass Spectrom.* **6**, 105-108.

Thornalley, P.J., Edwards, L.G., Kang, Y., Wyatt, C., Davies, N., Ladan, M.J., and Double, J. (1996). Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. *Biochem. Pharmacol.* **51**, 1365-1372.

10 Vancompernelle, K., Boonefaes, T., Mann, M., Fiers, W., and Grooten, J. (2000). Tumor necrosis factor-induced microtubule stabilization mediated by hyperphosphorylated oncoprotein 18 promotes cell death [In Process Citation]. *J. Biol. Chem.* **275**, 33876-33882.

15 Vince, R. and Wadd, W.B. (1969). Glyoxalase inhibitors as potential anticancer agents. *Biochem. Biophys. Res. Commun.* **34**, 593-598.

Wallach, D., Varfolomeev, E.E., Malinin, N.L., Goltsev, Y.V., Kovalenko, A.V., and Boldin, M.P. (1999). Tumor necrosis factor receptor and Fas signaling mechanisms. *Annu. Rev. Immunol.* **17**, 331-367.

20 Zhang, Y.H., Lin, J.X., Yip, Y.K., and Vilcek, J. (1988). Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: role in the induction of interleukin 6. *Proc. Natl. Acad. Sci. U. S. A* **85**, 6802-6805.

**CLAIMS**

1. A phosphorylated mammalian glyoxalase I.
2. The phosphorylated mammalian glyoxalase I according to claim 1, comprising  
5 SEQ ID N°1.
3. The use of a phosphorylated glyoxalase I and/or an inhibitor of the phosphorylation and/or a phosphorylation mutant of glyoxalase I to modulate MG-modification of proteins.
4. The use of a phosphorylated glyoxalase I and/or an inhibitor of the  
10 phosphorylation and/or a phosphorylation mutant of glyoxalase I to modulate TNF induced cell death.
5. The use of a phosphorylated glyoxalase I and/or an inhibitor of the phosphorylation and/or a phosphorylation mutant of glyoxalase I to modulate stress induced cell death.
- 15 6. The use of a phosphorylated glyoxalase I and/or an inhibitor of the phosphorylation and/or a phosphorylation mutant of glyoxalase I according to claim 5, whereby said stress is oxidative stress.
7. The use of a phosphorylated glyoxalase I and/or an inhibitor of the phosphorylation and/or a phosphorylation mutant of glyoxalase I according to  
20 claim 3-6, whereby said glyoxalase I is a mammalian glyoxalase I.
8. The use of a phosphorylated glyoxalase I and/or an inhibitor of the phosphorylation and/or a phosphorylation mutant of glyoxalase I according to claim 7, whereby said mammalian glyoxalase I is mutated at position 45 and/or 98 or any other mutant that affects phosphorylation at these or other sites
- 25 9. The use of a phosphorylated glyoxalase I and/or an inhibitor of the phosphorylation and/or a phosphorylation mutant of glyoxalase I according to claim 3-6, whereby said inhibitor is a PKA inhibitor.
10. The use of PKA to phosphorylate glyoxalase I.





1/8

Fig. 1





Fig. 3






2/8

Fig. 2

Effect of the glyoxalase I inhibitor on TNF-induced cytotoxicity  
in L929s cells





3/8

Fig. 4


**Effect of exogenously added methylglyoxal on TNF-induced****cell death**



Fig. 5


**Effect of aminoguanidine on TNF-induced cell death**





Fig. 6

# Inhibition of TNF-induced cell death by the PKA inhibitor H89







Fig.7





7/8

Fig. 8








Fig. 9







## SEQUENCE LISTING

&lt;110&gt; Vlaams Interuniversitair Instituut voor Biotechnolo

&lt;120&gt; PHOSPHORYLATED GLYOXALASE I AND ITS USE

&lt;130&gt; KVC/Gly/V079

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; 01200353.9

&lt;151&gt; 2001-01-31

&lt;160&gt; 1

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 184

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

<223> Lactoylglutathione lyase; Glyoxalase I: Accession  
Q04760

&lt;400&gt; 1

Met Ala Glu Pro Gln Pro Pro Ser Gly Gly Leu Thr Asp Glu Ala Ala

1

5

10

15

Leu Ser Cys Cys Ser Asp Ala Asp Pro Ser Thr Lys Asp Phe Leu Leu

20

25

30

Gln Gln Thr Met Leu Arg Val Lys Asp Pro Lys Lys Ser Leu Asp Phe

35

40

45

Tyr Thr Arg Val Leu Gly Met Thr Leu Ile Gln Lys Cys Asp Phe Pro

50

55

60

Ile Met Lys Phe Ser Leu Tyr Phe Leu Ala Tyr Glu Asp Lys Asn Asp

65

70

75

80

Il Pro Lys Glu Lys Asp Glu Lys Ile Ala Trp Ala Leu Ser Arg Lys

85

90

95

Ala Thr Leu Glu Leu Thr His Asn Trp Gly Thr Glu Asp Asp Ala Thr

100

105

110



Gln Ser Tyr His Asn Gly Asn Ser Asp Pro Arg Gly Phe Gly His Ile  
115 120 125

Gly Ile Ala Val Pro Asp Val Tyr Ser Ala Cys Lys Arg Phe Glu Glu  
130 135 140

Leu Gly Val Lys Phe Val Lys Lys Pro Asp Asp Gly Lys Met Lys Gly  
145 150 155 160

Leu Ala Phe Ile Gln Asp Pro Asp Gly Tyr Trp Ile Glu Ile Leu Asn  
165 170 175

Pro Asn Lys Met Ala Thr Leu Met  
180



# PATENT COOPERATION TREATY


From the INTERNATIONAL BUREAU

PCT

*am*  
*PS*

To:

VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR  
BIOTECHNOLOGIE VZW  
Rijvisschestraat 120  
B-9052 Zwijnaarde  
BELGIQUE



### Information on patient family members

PCT/EP 02/01118

Form PCT/ISA/210 (patent family annex) (July 1992)